Work

Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management

Year: 2023

Type: review

Abstract: Several monoclonal antibodies have been approved by the Food and Drug Administration (FDA) to treat allergic disorders, including omalizumab, dupilumab, mepolizumab, reslizumab, benralizumab, tralokinumab and tezepelumab, and their indications continue to expand. Although the risks associated with these agents are overall low, hypersensitivity reactions have been described and are reported more frequently with increased use. We provide a comprehensive review of clinical features, diagnosis and management of hypersensitivity reactions attributed to these agents. We aim to provide useful information for the clinician managing hypersensitivity reactions to these monoclonal antibodies, as well as highlight the need for future research to address specific gaps in knowledge.

Source: Frontiers in Allergy

DOI: 10.3389/falgy.2023.1219735

Authors: Andrea Sitek, Sergio E. Chiarella, Thanai Pongdee

Institutions: University of Kansas Medical Center, Mayo Clinic

Language: English

Topic: Drug-Induced Adverse Reactions

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,125